WCLC即将来袭！一文速览OA＋MA专场120＋重磅研究

OA01.01-Genetic and Air Pollution Scores Identify Individuals at Elevated Risk in a Lung Cancer Screening Cohort

基因和空气污染评分可识别肺癌筛查队列中高风险患者

L. Trap， Erasmus University Medical Center，伊拉斯姆斯大学医学中心

OA01.02-The Mirror Study: Tumor Microenvironment (TME) in Patients With Non-Small Cell Lung Cancer Exposed to Indoor Radon +/- Tobacco Smoke

Mirror：室内氡+/-烟草烟雾暴露对非小细胞肺癌患者肿瘤微环境的影响

M. Garcia de Herreros，Hospital Clinic Barcelona，巴塞罗那医院

Investigating the Association Between Procedure Duration of Coronary Angiography and Intervention and Postoperative Cancer Risk

冠状动脉造影术及介入治疗时长与术后癌症风险的相关性研究 

Y. Chen，广州医科大学
 
OA01.03-Lung Cancer Among People Who Never Smoked: Global Epidemiology and Initial Identification of Early Detection Biomarkers

从未吸烟人群中的肺癌：全球流行病学及早期检测生物标志物的初步鉴定

H. Robbins，International Agency for Research on Cancer，国际癌症研究机构 

OA02.01-SKYSCRAPER-05: Phase II Study of Perioperative Tiragolumab + Atezolizumab ±Chemotherapy in Locally Advanced Resectable NSCLC

SKYSCRAPER-05：围术期Tiragolumab联合阿替利珠单抗±化疗治疗局部晚期可切除非小细胞肺癌患者的II期临床研究

C.A. Sh，Herbert Irving Comprehensive Cancer Center，赫伯特·欧文综合癌症中心 

OA03.01-Multiomic Single Cell Profiling Reveals Novel Evolutionary Trajectories in Lung Carcinogenesis

多组学单细胞分析揭示肺癌致癌机制的全新进化轨迹

H. Hong，广东省人民医院

OA03.02-Deciphering Genomic Evolution of Metastatic Organotropism With Large-Scale Paired Primary Lung Cancers and Metastases.

通过大规模配对原发性肺癌和转移性肺癌样本分析揭示：转移性器官趋向性的基因组进化

W-F. Tang，广东省人民医院 

OA03.03-Rilvegostomig Enhances Ex Vivo Immune Activation in Patient-Resected NSCLC Tumors Over PDx or PDX/aTIGIT Combination Therapy.

与 PDx 或 PDX/aTIGIT 联合疗法相比，Rilvegostomig可增强切除 NSCLC 肿瘤的体外免疫激活。

J. Ratiu，阿斯利康 

OA03.04-TNFSF8-Targeting CpG Peptide Vaccine Reduces ICB Pneumonitis While Boosting Cancer Immunotherapy Efficacy.

靶向TNFSF8 CpG肽疫苗可降低ICB肺炎同时增强癌症免疫治疗效果

Z-X. Rong，南方医科大学南方医院  

OA04.01-Perceptions of Dyspnea and Quality of Life Before and After Lung-Sparing Surgery: A Pilot Mixed Methods Study

肺保留手术前后呼吸困难及生活质量的感知：一项混合方法试点研究

M. Culligan，Temple University Hospital，美国宾夕法尼亚州费城天普大学医院

OA04.02-Implementation of Large Language Model and GraphRAG-Assisted Decision Support for Multidisciplinary Team Cancer Care

大语言模型和GraphRAG辅助决策支持在多学科团队肿瘤诊疗中的应用

S. Chen，成都市第三人民医院

OA04.03-Association of Pre- and Postdiagnosis Physical Activity, Promotion, and Maintenance With Lung Cancer Survival: A Nationwide Cohort Study

诊断前后体力活动等与肺癌患者生存的相关性：一项全国性队列研究

Y.W. Kim，Seoul National University Bundang Hospital，首尔国立大学盆唐医院 

OA04.04-Resiliency Among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT): A Phase II - RCT Supportive Care Intervention.

接受癌症治疗老年肺癌患者的恢复力 (ROAR-LCT)：II 期 RCT 支持性护理干预

C. Presley，Ohio State University，俄亥俄州立大学医学院

OA05.01-ASTRUM-002: First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-Small Cell Lung Cancer.

ASTRUM-002：一线斯鲁利单抗联合化疗±HLX04治疗晚期非鳞状非小细胞肺癌的疗效

OA05.02-First-Line Atezolizumab Plus Chemotherapy in Elderly Patients With Advanced NSCLC, IFCT-1805 Elderly: A Randomized, Multicenter, Phase 3 Trial.

一线阿替利珠单抗联合化疗用于老年晚期非小细胞肺癌患者，IFCT-1805老年患者：一项随机、多中心、3期临床试验

OA05.03-NIVIPI-Brain: Phase 2 Study of Nivolumab + Ipilimumab Combined With Chemotherapy in NSCLC With Synchronous Brain Metastases.

NIVIPI-Brain：纳武利尤单抗+伊匹木单抗联合化疗治疗同时性脑转移非小细胞肺癌的2期临床研究

OA06.01-A First-In-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC.

靶向DLL3抗体偶联药物SHR-4849 (IDE849)治疗复发性小细胞肺癌的首次人体I期临床试验

王琳琳，山东第一医科大学附属肿瘤医院 

OA07.01-Final Analysis of Brighstar: LCT With Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC.

Brighstar：LCT联合布格替尼治疗酪氨酸激酶抑制剂初治ALK重排转移性非小细胞肺癌的最终分析

OA07.02-Tumor Burden Metrics at Oligoprogression and Survival After SBRT in NSCLC: An Analysis of the Randomized Phase II CURB Trial.

非小细胞肺癌立体定向放射治疗（SBRT）后寡进展期肿瘤负荷指标及生存期：2期随机CURB试验

M.T. McMillan，Memorial Sloan-Kettering Cancer Center，纪念斯隆凯特琳癌症中心

OA07.03-Stereotactic Ablative Radiotherapy in Oligo-Metastatic NSCLC Patients:START NEW ERA#OLIGO Non-Randomised Phase II Trial.

寡转移性非小细胞肺癌患者的立体定向消融放射治疗：开启新时代#OLIGO非随机II期临床试验

F. ARCIDIACONO，  "S. Maria" Hospital，意大利特尔尼市“圣玛丽亚”医院 

OA07.04-Molecular and Early Outcomes of a Randomized Phase II Trial of Primary Tumor Resection Following EGFR TKI in Metastatic NSCLC.

转移性非小细胞肺癌EGFR TKI治疗后切除原发肿瘤的的分子特征和早期结果：随机II期临床试验

OA08.01-BMS-986504 in Patients With Homozygous MTAP-Deletion (Del): Clinical Results in Patients With NSCLC Enrolled in CA240-0007.

BMS-986504治疗纯合MTAP缺失(Del)患者：入组CA240-0007非小细胞肺癌患者的临床结果

OA08.02-Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01.

一线Olomorasib联合免疫/化疗治疗KRAS G12C突变非小细胞肺癌的疗效和安全性：来自LOXO-RAS-20001和SUNRAY-01研究

M.V. Negrao ，MD Anderson Cancer Center，MD安德森癌症中心

OA08.03-COMPEL: Osimertinib + Platinum-Based Chemotherapy in Patients With EGFRm Advanced NSCLC and Progression on 1L Osimertinib.

COMPEL：奥希替尼联合含铂化疗用于一线奥希替尼治疗后进展的EGFR突变晚期非小细胞肺癌

OA09.01-Machine Learning Assessment of Pathologic Response in Lung Resections After Neoadjuvant Therapy - IASLC MPR Project.

新辅助治疗后肺切除术病理反应的机器学习评估 - IASLC MPR 项目

S. Dacic，Yale School of Medicine，耶鲁大学医学院  

OA10.01-Intracranial Efficacy of Datopotamab Deruxtecan (Dato-DXd) in Patients With Advanced/Metastatic NSCLC in TROPION-Lung01.

TROPION-Lung01研究：Datopotamab Deruxtecan (Dato-DXd)对晚期/转移性非小细胞肺癌患者的颅内疗效

E. Pons-Tostivint，University Hospital of Nantes，南特大学医院 

OA10.02-Bevacizumab Plus Chemotherapy Versus Chemotherapy in Untreated Non-Squamous NSCLC With Brain Metastases: A Randomized, Phase 3 Study.

一线贝伐珠单抗联合化疗对比化疗治疗非鳞状非小细胞肺癌脑转移的疗效：一项随机、3期临床研究

OA10.03-Phase I/II Study of Iza-Bren (BL-B01D1) as Monotherapy in Patients With Locally Advanced or Metastatic EGFR Mutated NSCLC.

Iza-Bren (BL-B01D1) 单药治疗局部晚期或转移性EGFR突变非小细胞肺癌患者的I/II期临床研究

方文峰，中山大学肿瘤防治中心 

OA10.04-Phase II Study of Iza-Bren (BL-B01D1) Combo With Osimertinib in EGFR Mutated Locally Advanced or Metastatic NSCLC Patients.

Iza-Bren (BL-B01D1) 联合奥希替尼治疗EGFR突变局部晚期或转移性非小细胞肺癌患者的II期临床研究

周斐，上海市东方医院 

OA11.01-Impact of Smoking Status on the Prognosis of Lung Cancer in the IASLC Ninth Edition TNM Classification Database.

吸烟状况对IASLC第九版TNM分期数据库中肺癌预后的影响

L. Eng，Princess Margaret Cancer Centre，玛格丽特公主癌症中心  

OA11.02-Molecular Alterations and Survival: Analyses From IASLC 9Th Edition Staging Database.

分子改变与生存：基于IASLC第9版分期数据库的分析

F.R. Hirsch，Icahn School of Medicine at Mount Sinai，纽约市西奈山医学院

OA11.03-The Survival Impact of Subdividing Clinical and Pathologic N2 Descriptors in a Population-Based Surgical Cohort.

在基于人群的外科手术队列中细分临床和病理N2对生存的影响

J. Rice，University of Memphis School of Public Health，孟菲斯大学公共卫生学院 

OA11.04-Validation and Refinement Proposal of the Ninth Edition n Descriptor for Non-Small Cell Lung Cancer Receiving Neoadjuvant Therapy.

第九版非小细胞肺癌新辅助治疗N描述符的验证及改进建议

H. Si，上海市肺科医院 

OA12.01-ASLC Mesothelioma Staging Project: Impact of Molecular Alterations on Survival in a Cohort From 9Th Edition Database.

ASLC间皮瘤分期项目：分子改变对第九版数据库队列生存的影响

J.L. Sauter，Memorial Sloan Kettering Cancer Center，纪念斯隆凯特琳癌症中心 

OA12.02-CTG IND227, a Randomized Trial of Chemotherapy + Pembrolizumab in Advanced Pleural Mesothelioma: Updated Analyses.

CTG IND227，一项化疗+帕博利珠单抗治疗晚期胸膜间皮瘤的随机试验：最新分析

S. Laurie，Ottawa Hospital Research Institute，渥太华医院研究所 

OA12.03-Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Resectable Diffuse Pleural Mesothelioma.

可切除弥漫性胸膜间皮瘤的新辅助治疗：纳武利尤单抗或纳武利尤单抗联合伊匹木单抗

J. Reuss，ohns Hopkins Sidney Kimmel Comprehensive Cancer Center，约翰斯·霍普金斯大学西德尼·金梅尔综合癌症中心 

OA12.04-Radiation Reprograms CDKN2A/p16 Wild Type Epithelioid Mesothelioma Towards an Immune Responsive Tumor Microenvironment.

放射疗法重构CDKN2A/p16野生型上皮样间皮瘤，使其向免疫应答性肿瘤微环境发展

M. De Perrot，Princess Margaret Cancer Centre，玛格丽特公主癌症中心 

OA13.01-Hypofractionated vs Conventional Fractionated Radiotherapy With Concurrent Chemotherapy for LS-SCLC: A Multi-Center Phase III Trial.

低分割放疗 vs 常规分割放疗联合同步化疗治疗局限期小细胞肺癌：一项多中心III期临床试验

毕楠，中国医学科学院肿瘤医院 

OA14.01-Glutamine Metabolic Reprogramming Drives Evolution of Lung Adenocarcinoma.

谷氨酰胺代谢重编程驱动肺腺癌进化

Y. Wang，上海市肺科医院 

OA14.02-DCBLD2 high Tumor-Derived Retinoic Acid Orchestrates Macrophages to Drive Vascular Immunosuppression and Immunotherapy Resistance.

DCBLD2高肿瘤衍生的视黄酸调控巨噬细胞驱动血管免疫抑制和免疫治疗耐药

S. Li，南方医科大学南方医院 

OA14.03-Functional Characterization of Osimertinib-Induced Drug Tolerant Persisters in Lung Adenocarcinoma.

肺腺癌中奥希替尼诱导耐受持续性的功能特征

K.A. Gorospe，University of Toronto，多伦多大学 

OA14.04-Genetic Inactivation of the Epigenetic Regulator ATF7IP: Functional Impact in Lung Adenocarcinomas.

表观遗传调节因子ATF7IP基因组失活：对肺腺癌的功能影响

J.M. Morillas，Josep Carreras Leukemia Research Institute，何塞普·卡雷拉斯白血病研究所 

OA15.01-Comparing 74 vs 80 as the Upper Age Limit for Lung Cancer Screening: A Multi-Centre Cohort Study.

74岁 vs 80岁作为肺癌筛查的年龄上限：一项多中心队列研究

P. Goodley，Manchester University NHS Foundation Trust，曼彻斯特大学NHS基金会 

OA15.02-Results of the Croatian National Lung Cancer Screening Program.

克罗地亚国家肺癌筛查计划结果

M. Samaržija， University hospital centre Zagreb，萨格勒布大学医院中心 

OA15.03-Preliminary Results of the Singapore Lung Cancer Screening Through Integrating CT With Other Biomarkers (SOLSTICE) Study.

CT联合其他生物标志物进行的新加坡肺癌筛查研究初步结果（SOLSTICE）

G.G.Y. Lai，National Cancer Centre Singapore，新加坡国家癌症中心 

OA15.04-Female Asian Nonsmoker Screening Study (FANSS): A U.S. Based Lung Cancer Screening Program in a Non-Smoking Population.

亚裔女性非吸烟者筛查研究 (FINDS)：一项针对美国非吸烟人群的肺癌筛查项目

E. Shum，NYU Perlmutter Cancer Center，纽约大学珀尔马特癌症中心 

OA16.01-Thymus Dosimetry and the RTOG 0617 Paradox: A Novel Immunologic Hypothesis.

胸腺剂量测定与RTOG 0617悖论：一种新的免疫学假说

T.L. Chaunzwa，Memorial Sloan Kettering Cancer Center，纪念斯隆凯特琳癌症中心

OA16.02-RAPID-RT: Using Rapid-Learning to Assess the Survival Impact of Limiting Dose to a New Cardiac Avoidance Area During Lung Cancer Radiotherapy.

RAPID-RT：利用快速学习评估肺癌放射治疗期间限制新心脏避让区剂量对生存的影响

C. Faivre-Finn，The University of Manchester，曼彻斯特大学 

MA01.01-Surgical Outcomes and Oncological Quality of Surgery According to IASLC Criteria in NADIM II Trial.

根据 IASLC 标准评估 NADIM II 试验中的手术结果和肿瘤学质量

J.R. JARABO，Hospital Clínico San Carlos，西班牙马德里圣卡洛斯医院 

MA01.02-Prognostic Value of Residual Viable Tumor in Lymph Nodes of Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy.

非小细胞肺癌新辅助免疫/化疗治疗后淋巴结内残留活肿瘤的预后价值

T. Han，北京大学人民医院 

MA01.03-Metabolomic Analysis Identifies Histamine as a Key Predictive Factor for Perioperative Chemoimmunotherapy in NADIM II Trial.

NADIM II 试验中代谢组学分析确定组胺是围手术期免疫/化疗治疗的关键预测因素

P. Mediavilla-Medel，Hospital Universitario Puerta de Hierro-Majadahonda，普埃尔塔德埃耶罗大学医院 

MA01.04-Neoadjuvant PD-(L)1 Blockade in Combination With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.

新辅助PD-(L)1单抗联合化疗治疗边缘可切除和不可切除的III期非小细胞肺癌

B. Ricciuti，Dana-Farber Cancer Institute，丹娜-法伯癌症研究所 

MA01.05-Tislelizumab Plus Chemotherapy Followed by Surgery or Radiotherapy and Adjuvant Tislelizumab in Unresectable Stage III NSCLC.

替雷利珠单抗联合化疗，序贯手术或放疗及替雷利珠单抗辅助治疗治疗不可切除的III期非小细胞肺癌

J. Liu，四川大学华西医院 

MA01.06-Phase I/II Trial of Canakinumab With Chemoradiation and Durvalumab in Stage III Non-Small Cell Lung Cancer (ChHORUS)

Canakinumab联合放化疗和度伐利尤单抗治疗 III 期非小细胞肺癌的 I/II 期临床试验 (ChHORUS)

N. Shaverdian，Memorial Sloan Kettering Cancer Center，纪念斯隆凯特琳癌症中心 

MA01.07-Preliminary Results of the Phase I LuCa-MERIT-1 Trial: An Advanced NSCLC pt Cohort Treated With BNT116 + Cemiplimab Post CRT.

I期LuCa-MERIT-1试验初步结果：CRT后BNT116 + Cemiplimab治疗晚期非小细胞肺癌患者

B.B. Öven，Yeditepe University Hospital，Yeditepe大学医院 

MA01.08-Sequential Chemo-SAbR Following by Immunotherapy in Unresectable LA-NSCLC Unfit for Concurrent ChT-RT According to the START-NEW-ERA Trial.

根据START-NEW-ERA试验，对于不适合同步化疗-放疗的不可切除局部晚期非小细胞肺癌患者，进行顺序化疗-SAbR序贯免疫治疗

P. ANSELMO，Radiotherapy Oncology Centre "S.Maria" Hospital，“S.Maria”医院肿瘤放射治疗中心 

MA01.09-Sequencing of Radiotherapy and Immunotherapy Stratifies Pneumonitis Risk: A Propensity-Matched Multicenter Study.

放疗和免疫治疗的排序对肺炎风险的分层：一项倾向匹配的多中心研究

W. Wei，襄阳市中心医院 

MA02.01-Contemporary Landscape of Acquired Resistance to Next-Generation ALK Inhibitors: Paired Pre-/Post-Treatment Biopsy Analysis .

新一代 ALK 抑制剂的获得性耐药概况：治疗前/治疗后配对活检分析

S. Waliany，Massachusetts General Hospital Cancer Center，麻省总医院癌症中心 

MA02.02-Updated Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study.

他雷替尼在ROS1+非小细胞肺癌患者中的疗效和安全性更新：全球TRUST-II 研究

G. Liu，Princess Margaret Cancer Centre，玛格丽特公主癌症中心 

MA02.03-Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Long-Term Follow-Up From the Phase 1/2 TRIDENT-1 Trial.

瑞普替尼治疗ROS1+非小细胞肺癌患者：1/2期TRIDENT-1试验的长期随访结果

B.C. Cho，Yonsei University College of Medicine，延世大学医学院延世癌症中心

MA02.04-Updated Efficacy, Safety, and Genomic Data in Patients With Trk Fusion Lung Cancer Treated With Larotrectinib

拉罗替尼治疗Trk融合肺癌患者的疗效、安全性及基因组学数据更新

J.J. Lin，Massachusetts General Hospital & Harvard Medical School，麻省总医院&哈佛医学院 

MA02.05-Liquid Biopsy in BRAF V600E NSCLC Treated With Dabrafenib Plus Trametinib: Final Analysis of LiBRA Study (GOIRC-03-2020).

达拉非尼联合曲美替尼治疗BRAF V600E非小细胞肺癌的液体活检：LiBRA研究最终分析 (GOIRC-03-2020)

A. Leonetti，University Hospital of Parma，意大利帕尔马大学医院 

MA02.06-Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01.

Olomorasib＋帕博利珠单抗在KRAS G12C突变NSCLC中的疗效和安全性：来自LOXO-RAS-20001和SUNRAY-01研究

M.L. Johnson，Sarah Cannon Research Institute，莎拉坎农研究所 

MA02.07-Upfront Management of Brain Metastases (BM) in Oncogene-Addicted NSCLC Treated With Targeted Therapies: An EORTC Survey.

致癌基因驱动非小细胞肺癌脑转移 (BM) 靶向治疗的早期管理：一项 EORTC 调查

A. Ortega-Franco，The Christie NHS Foundation Trust，克里斯蒂NHS基金会

MA03.01-Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC.

超灵敏MRD可提高可切除I期非小细胞肺癌的检出率

Z. Coyne，Princess Margaret Cancer Centre，玛格丽特公主癌症中心 

MA03.02-Clinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC.

基于肿瘤全基因组的ctDNA检测在预测早期可切除非小细胞肺癌复发中的临床应用

G. Becharano，Baylor Scott and White Research Institute，贝勒斯科特和怀特研究所 

MA03.03-SAVANNAH: Biomarker Concordance and Acquired Resistance to Osi+Savo in Patients With EGFRm MET-OverExp And/Or Amp NSCLC.

SAVANNAH：EGFR突变伴MET过表达和/或扩增NSCLC患者的生物标志物一致性以及奥希替尼联合赛沃替尼的获得性耐药分析

C. Baik，University of Washington School of Medicine，美国华盛顿大学医学院弗雷德·哈钦森癌症中心 

MA03.04-Comparative Analysis of Circulating Tumor DNA Monitoring Strategies in Advanced NSCLC With MET Exon 14 Skipping Treated With Ensartinib.

恩沙替尼治疗MET外显子14跳跃突变晚期非小细胞肺癌的ctDNA监测策略比较分析

夏旸，浙江大学医学院附属第二医院 

MA03.05-Circulating Tumor DNA Tumor Fraction as a Precision Biomarker for Radiotherapy in Oligometastatic NSCLC

ctDNA肿瘤组分作为寡转移性非小细胞肺癌放射治疗的精准生物标志物

K. Parikh，Mayo Clinic，梅奥诊所 

MA03.06-Intrathecal Pemetrexed for Lung Adenocarcinoma Leptomeningeal Metastasis: A Study on Efficacy and Liquid Proteomics

鞘内注射培美曲塞治疗肺腺癌软脑膜转移：疗效及液体蛋白质组学研究

董晓荣，华中科技大学同济医学院附属协和医院

MA03.07-Multi-Omic Analyses of CSF Reveal Genomic Instability and Suppressed Microenvironment After TKI Resistance in Patients With Brain Metastases

脑脊液多组学分析揭示：脑转移患者TKI耐药后基因组不稳定性及微环境抑制

M. Li，中山大学肿瘤防治中心 

MA03.08-Identification of Circulating microRNA Signature for Diagnosis and Prognosis of Checkpoint Inhibitor-Related Pneumonitis

循环microRNA特征的鉴定及其在免疫检查点抑制剂相关性肺炎诊断和预后中的应用

H. Deng，广州医科大学附属第一医院 

MA03.09-Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive-Stage Small Cell Lung Cancer

一线斯鲁利单抗联合化疗治疗广泛期小细胞肺癌的MRD动态监测分析

K. Ma，吉林大学第一医院 

MA04.01-No Versus Systematic Mediastinal LN Dissection for GGO-Dominant Lung Adenocarcinoma: A Multicenter, Phase III, Non-Inferiority RCT

GGO 为主型肺腺癌患者不进行纵隔淋巴结清扫术与系统性纵隔淋巴结清扫术的比较：一项多中心、III期、非劣效性随机对照试验

Y. Zhang，复旦大学附属肿瘤医院 

MA04.02-Nautika1: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC

Nautika1：阿来替尼新辅助治疗在可切除IB-IIIB期ALK+ NSCLC中的临床疗效和病理退缩

J.M. LEE，University of California，加州大学洛杉矶分校 

MA04.03-Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A EGFR Mutated NSCLC With High Risk (APPOINT)

阿美替尼作为可切除IA期EGFR突变高危非小细胞肺癌辅助治疗的疗效和安全性（APPOINT）

W. Zhang，上海交通大学附属胸科医院 

MA04.04-Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study

围术期帕博利珠单抗治疗非小细胞肺癌的疗效：KEYNOTE-671研究中不同淋巴结状态患者的4年疗效结果

H. Wakelee，Stanford University，斯坦福大学 

MA04.05-Patient-Reported Outcomes With Perioperative Nivolumab by Nodal Status in Patients With Resectable NSCLC From Checkmate 77T

Checkmate 77T：不同淋巴结状态可切除非小细胞肺癌接受围术期纳武利尤单抗治疗的患者报告结局

J.D. Spicer，McGill University Health Centre，麦吉尔大学健康中心 

MA04.06-Neoadjuvant Pembrolizumab: Multi-Omics Characterization of the Tumoral Immune Response Reveals Distinct Mechanisms of Action

帕博利珠单抗新辅助治疗：肿瘤免疫反应的多组学特征揭示不同的作用机制

B. Niedermaier，University Hospital Heidelberg，海德堡大学医院

MA04.07A-Phase 2 Multicenter Umbrella Trial Assessing Tislelizumab ± Anti-TIGIT or Anti-LAG-3 mAb ± Chemotherapy in Resectable NSCLC

2期多中心伞状试验，评估替雷利珠单抗±抗TIGIT或抗LAG-3单抗±化疗在可切除非小细胞肺癌患者中的疗效

P. Zhang，上海市肺科医院 

MA07.01A-Grading System for Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee

肺浸润性鳞状细胞癌分级系统：IASLC 病理学委员会的一项多机构研究

M. Mino-Kenudson，Massachusetts General Hospital, 麻省总医院 

MA07.02-Development and Prospective Validation of a Chromatin-Based Classification for Small-Cell Lung Cancer

基于染色质的小细胞肺癌分类方法的开发及前瞻性验证

A. Thomas，NIH，美国国立卫生研究院 

MA07.03-Morphological Implication of Invasive Lung Adenocarcinoma -Analysis Employing AI Method Based on Noguchi’s Classification

侵袭性肺腺癌的形态学意义——基于Noguchi分类的人工智能方法分析

H. Kawaii，University of Tsukuba，筑波大学 

MA07.04-Integration of a Molecular Prognostic Classifier Enhances Conventional Staging of Lung Adenocarcinoma

分子预后分类的整合增强肺腺癌的传统分期

H. Abolfathi，Institut Universitaire de Cardiologie et de Pneumologie de Québec，魁北克心脏病和肺病学研究所 

MA07.05-Lung Cancer With Spread of Tumor Through Air Spaces: Transcriptomic Biosignature of Primary Tumors and Expression Analysis Airway Tumor Clusters

肺癌伴肿瘤经气腔播散：原发性肿瘤的转录组生物特征及气道肿瘤簇表达分析

W.S. Brandt，Washington University St. Louis，华盛顿大学圣路易斯分校 

MA07.06-Characterization of Protein Arginine Methyltransferase 5 (PRMT5) Expression in Methylthioadenosine Phosphorylase (MTAP) Deleted NSCLC

甲基硫腺苷磷酸化酶 (MTAP) 缺失的非小细胞肺癌中蛋白质精氨酸甲基转移酶 5 (PRMT5) 表达的特征

R. Hsu，University of Southern California, 南加州大学 

MA07.07-Validation Analysis of MET Ihc as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib Egfr-Mutated NSCLC

MET IHC作为奥希替尼治疗后EGFR突变NSCLC患者埃万妥单抗-兰泽替尼疗效生物标志物的验证分析

B. Besse，Saclay University, Institut Gustave Roussy，巴黎萨克雷大学古斯塔夫·鲁西研究所 

MA07.08-MFAP4+ Pericytes Promote Tc17-Mediated Pneumonitis Induced by the Combination of Radiotherapy & Immunotherapy

MFAP4+周细胞促进放疗和免疫疗法联合诱导的Tc17介导性肺炎

X. Bai，南方医科大学 

MA07.09-Three-Year Survival Update and Biomarker Analysis of Neoadjuvant Chemoimmunotherapy in Potentially Resectable Stage IIIA/IIIB NSCLC

潜在可切除IIIA/IIIB期非小细胞肺癌新辅助化学免疫/化疗治疗的3年生存率更新及生物标志物分析

K. Ma，吉林大学第一医院 

MA08.01A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC With EGFR Exon 20 Insertion Mutations

舒沃替尼治疗EGFR外显子20插入突变非小细胞肺癌的多地区/中心2期随机关键性研究

王孟昭，北京协和医院 

MA08.02-Zipalertinib in NSCLC Patients (Pts) With EGFR Exon 20 Insertion (Ex20Ins) Mutations Who Received Prior Amivantamab

Zipalertinib治疗既往接受过埃万妥单抗的EGFR 20 外显子插入突变非小细胞肺癌患者的疗效

Z. Piotrowska，MASSACHUSETTS GENERAL HOSPITAL，麻省总医院 

MA08.03-First-Line Subcutaneous Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion-Mutated Advanced NSCLC: Results From PALOMA-2

EGFR 20外显子插入突变晚期非小细胞肺癌一线埃万妥单抗（皮下注射）联合化疗：PALOMA-2研究结果

S-M. Lim，Yonsei University College of Medicine，延世大学医学院 

MA08.04-Phase 2 Interim Results of Zipalertinib in Patients With NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR Mutations

Zipalertinib治疗携带罕见非20外显子插入突变EGFR突变非小细胞肺癌患者的 II 期中期结果

H. Udagawa，National Cancer Center Hospital East，柏市国立癌症中心东医院 

MA08.05-PALOMA-2: Subcutaneous Amivantamab Administered Every 4 Weeks (Q4W) Plus Lazertinib in First-Line EGFR-Mutated Advanced NSCLC

PALOMA-2：皮下注射埃万妥单抗（每4周一次）联合兰泽替尼一线治疗EGFR突变晚期非小细胞肺癌

S.C. Scott，Johns Hopkins University School of Medicine，霍普金斯大学医学院 

MA08.06-Comparison of Asandeutertinib and Osimertinib in EGFR-Mutated NSCLC With Brain Metastases: Interim Analysis of the ESAONA Pivotal Study 

Asandeutertinib对比奥希替尼治疗EGFR突变非小细胞肺癌脑转移的疗效：ESAONA关键性研究的中期分析

石远凯，中国医学科学院肿瘤医院  

MA10.01-Phase II Trial Of serplulimab Plus Bevacizumab and Chemotherapy for treatment-Naïve Non-Squamous NSCLC With Brain Metastases(SUPER BRAIN)

斯鲁利单抗联合贝伐珠单抗及化疗治疗非鳞状非小细胞肺癌脑转移的II期临床试验（SUPER BRAIN）

H. Yu，广州中山大学肿瘤防治中心  

MA10.02-CAN-2409 With Continued Immune Checkpoint Inhibitor (ICI) in Patients With Stage III/IV NSCLC With Inadequate Response to ICI

CAN-2409 联合持续免疫检查点抑制剂(ICI)治疗对ICI疗效不佳的III/IV期非小细胞肺癌患者

C. Aggarwal，Penn Medicine， 宾夕法尼亚大学医学院 

MA10.03-Efficacy and Safety of Cadonilimab Plus Pulocimab in NSCLC Patients Who Progressed Following Prior Immunotherapy: A Phase 1b/2 Study

卡度尼利单抗联合Pulocimab治疗既往免疫治疗后疾病进展非小细胞肺癌患者的疗效和安全性：一项1b/2期临床研究

Y. Zheng，浙江大学医学院附属第一医院 

MA10.04-Low-Pass Wgs Reveals Clonal Evolution of CNAs Associated With Response to the First-Line Immunotherapy or Chemoimmunotherapy in NSCLC Patients

低深度高通量Wgs揭示与非小细胞肺癌患者一线免疫疗法或化学免疫疗法疗效相关的CNA克隆进化

M. Nicoś，Medical University of Lublin，卢布林医科大学，

MA10.05-Phase I/II Study of Nivolumab and Ipilimumab With Concurrent Stereotactic Radiosurgery for Intracranial Metastases From NSCLC

纳武利尤单抗和伊匹木单抗联合立体定向放射外科治疗非小细胞肺癌颅内转移的 I/II 期临床研究

M. Altan，MD Anderson Cancer Center MD，安德森癌症中心 

MA10.06-IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration

IMscin002最终分析：皮下和静脉注射阿替利珠单抗的患者偏好和安全性

F. Cappuzzo，IRCCS Istituto Nazionale Tumori Regina Elena，IRCCS里贾纳埃琳娜国立肿瘤研究所 

MA10.07-Impact of Myeloid Growth Factor Support on Outcomes in RELATIVITY-104: Insights From Clinical and Preclinical Data in NSCLC

髓系生长因子支持对RELATIVITY-104研究结果的影响：基于非小细胞肺癌临床和临床前数据的洞察

V. Velcheti，NYU Langone Perlmutter Cancer Center， 纽约大学朗格尼-珀尔马特癌症中心 

MA10.08-Anti-PD-1 Re-Challenge After Immune Priming by CTLA-4 Inhibition and Immune Boosting Through Radiotherapy in Advanced NSCLC: The RAD-IO Trial

晚期非小细胞肺癌患者在CTLA-4抑制免疫启动和放射治疗免疫增强后再次接受抗PD-1治疗：RAD-IO试验

D. van der Geest，NKI-AvL，荷兰癌症研究所安东尼·范·列文虎克医院

MA11.01-Phase 1 Study of DLL3-Targeted CAR-T Cells Armored With dnTGFBR2 in Small-Cell Lung and Large-Cell Neuroendocrine Cancers

靶向DLL3的CAR-T细胞（dnTGFBR2修饰）治疗小细胞肺癌和大细胞神经内分泌癌的 I 期研究

A.J. Schoenfeld，Memorial Sloan Kettering Cancer Center，纪念斯隆凯特琳癌症中心 

MA11.02-RYZ101 (225Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor-Expressing Extensive-Stage SCLC

RYZ101 (225Ac-DOTATATE) +卡铂+依托泊苷+阿替利珠单抗治疗表达生长抑素受体的广泛期小细胞肺癌

A.S. Mansfield，Mayo Clinic，梅奥诊所 

MA11.03-Tifcemalimab Plus Toripalimab and Chemotherapy as a First-Line Therapy in ES-SCLC: A Phase Ib/II Study

Tifcemalimab联合特瑞普利单抗及化疗一线治疗ES-SCLC：一项Ib/II期临床研究

李子明，上海市胸科医院 

MA11.04-Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results From the Phase 3 IMforte Study

芦比替定+阿替利珠单抗作为ES-SCLC一线维持治疗的安全性：3期IMforte 研究结果

M. Reck，Lungen Clinic 

MA11.05-Comparative Outcomes of Lobectomy and Sub-Lobar Resections in Pulmonary Carcinoids: A Multicentre Retrospective Cohort Study

肺叶切除术与亚肺叶切除术治疗肺类癌的疗效比较：一项多中心回顾性队列研究 

M. Dziedzic，Medical University of Gdańsk，格但斯克医科大学 

MA11.06-Multiomic Profiling of Inter-Lesion Heterogeneity in Small Cell Lung Cancer: A Multicenter Rapid Research Autopsy Program

小细胞肺癌病变间异质性的多组学分析：一项多中心快速研究尸检项目

Z. Megyesfalvi，Medical University of Vienna，维也纳医科大学 

MA11.07-Highly Proliferative (G3) Lung Carcinoids: IASLC Pathology Committee Study With Proposal for Inclusion in WHO Classification

高度增生性（G3）肺类癌：IASLC病理学委员会研究及WHO分类提案

N. Rekhtman，Memorial Sloan Kettering Cancer Center，纪念斯隆凯特琳癌症中心 

MA11.08-Longitudinal Circulating Tumor DNA Dynamics Predict Therapeutic Efficacy in ES-SCLC Treated With Immunotherapy

纵向循环肿瘤DNA动态变化预测ES-SCLC免疫治疗的疗效

苏春霞，上海同济大学医学院附属上海市肺科医院暨胸部肿瘤研究所 

MA11.09-Circulating Tumor DNA Refines Consolidation Immunotherapy for Limited-Stage SCLC

ctDNA完善局限期SCLC的巩固免疫治疗

毕楠，中国医学科学院肿瘤医院 

MA11.10-IFITM3 Enhances Immunotherapy Sensitivity Through MHC-I Regulation in Small Cell Lung Cancer

IFITM3通过调控MHC-I分子增强小细胞肺癌的免疫治疗敏感性

X. Liu，上海同济大学医学院附属肺科医院